Suppr超能文献

忽视每年重新评估医疗保险处方药计划供应的潜在机会成本:满足感的代价?

Potential opportunity cost of neglecting to annually reassess Medicare Part D standalone prescription drug plan offerings: the price of contentment?

机构信息

Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95204, USA.

出版信息

J Am Pharm Assoc (2003). 2009 Nov-Dec;49(6):777-82. doi: 10.1331/JAPhA.2009.09017.

Abstract

OBJECTIVES

To determine the (1) potential cost difference (opportunity cost [OC]) to Medicare-eligible beneficiaries enrolled in the lowest-cost standalone prescription drug plan (PDP) in 2007 between the cost of such plan in 2008 and the lowest-cost plan in 2008 and the (2) percentage of PDPs with the lowest estimated annual cost (EAC) in both 2007 and 2008.

DESIGN

Descriptive exploratory study.

SETTING

United States during 2007 and 2008.

PATIENTS

50 patients were randomly selected from a database of Medicare-eligible beneficiaries.

INTERVENTION

Pharmacy claims records for each study patient were obtained during the period January 1 to June 30, 2007. Patient medication profiles were generated using these data and entered into the Medicare Plan Finder Tool (www.medicare.gov) to obtain the EAC of each PDP from 2007 and 2008 in all 34 Medicare Part D regions.

MAIN OUTCOME MEASURES

The 2008 EAC of the lowest-cost PDP from 2007 was recorded. OC was determined by subtracting the 2008 EAC of the lowest-cost PDP in 2008 from the 2008 EAC of the lowest-cost PDP in 2007 for each patient in each region. The percentage of PDPs that had the lowest EAC in both 2007 and 2008 was recorded.

RESULTS

The 2008 EACs of the lowest-cost PDPs from 2007 were significantly higher (P < 0.001) than the lowest-cost PDPs of 2008 within all 34 Medicare regions. The mean OC ranged from $276 to $562 nationally. Only 12% of plans were the lowest-cost PDP in both 2007 and 2008.

CONCLUSION

Medicare beneficiaries should reevaluate PDP offerings annually during the open enrollment period; failure to do so may increase avoidable out-of-pocket costs.

摘要

目的

确定(1)2007 年参加最低成本独立处方药计划(PDP)的符合医疗保险条件的受益人在 2008 年与 2008 年最低成本计划之间的潜在成本差异(机会成本[OC]),以及(2)2007 年和 2008 年中所有 34 个医疗保险 D 部分地区中最低估计年度成本(EAC)最低的 PDP 的百分比。

设计

描述性探索性研究。

地点

2007 年和 2008 年期间的美国。

患者

从符合医疗保险条件的受益人的数据库中随机选择了 50 名患者。

干预措施

在 2007 年 1 月 1 日至 6 月 30 日期间,获得每位研究患者的药房理赔记录。使用这些数据生成患者用药概况,并将其输入医疗保险计划查找工具(www.medicare.gov),以获取 2007 年和 2008 年所有 34 个医疗保险 D 部分地区每个 PDP 的 EAC。

主要观察指标

记录 2008 年最低成本 PDP 的 2008 年 EAC。对于每个地区的每位患者,通过从 2008 年最低成本 PDP 的 2008 年 EAC 中减去 2007 年最低成本 PDP 的 2008 年 EAC 来确定 OC。记录在 2007 年和 2008 年均具有最低 EAC 的 PDP 的百分比。

结果

在所有 34 个医疗保险 D 部分地区,2007 年最低成本 PDP 的 2008 年 EAC 明显高于(P <0.001)2008 年最低成本 PDP。全国范围内,平均 OC 范围为 276 美元至 562 美元。只有 12%的计划在 2007 年和 2008 年均为最低成本 PDP。

结论

医疗保险受益人应在开放注册期间每年重新评估 PDP 产品;未能这样做可能会增加可避免的自付费用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验